21-34887039-A-T
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BS1
This summary comes from the ClinGen Evidence Repository: The NM_001754.4:c.155T>A (p.Met52Lys) is a missense variant. This variant has a MAF of 0.0007121 (0.071%, 840/1179678, 840 alleles) in the European (non-Finnish) subpopulation of the gnomAD v4.1.0 cohort is between 0.00015 (0.015%) and 0.0015 (0.15%) (BS1). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BS1. LINK:https://erepo.genome.network/evrepo/ui/classification/CA10014581/MONDO:0011071/008
Frequency
Consequence
NM_001754.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -4 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000270 AC: 41AN: 152132Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000258 AC: 60AN: 232566Hom.: 0 AF XY: 0.000249 AC XY: 32AN XY: 128548
GnomAD4 exome AF: 0.000597 AC: 865AN: 1449282Hom.: 1 Cov.: 35 AF XY: 0.000560 AC XY: 404AN XY: 721512
GnomAD4 genome AF: 0.000270 AC: 41AN: 152132Hom.: 0 Cov.: 32 AF XY: 0.000215 AC XY: 16AN XY: 74312
ClinVar
Submissions by phenotype
not provided Uncertain:2
The RUNX1 p.M52K variant was identified in the literature in two individuals with acute myeloid leukemia (Mendler_2013_PMID:23753029; Drazer_2018_PMID:29365323). The variant was identified in dbSNP (ID: rs200431130) and ClinVar (classified as uncertain significance by the ClinGen Myeloid Malignancy Variant Curation Expert Panel, Invitae, and three other laboratories). The variant was identified in control databases in 65 of 263936 chromosomes at a frequency of 0.0002463, and was observed at the highest frequency in the European (non-Finnish) population in 61 of 122518 chromosomes (freq: 0.0004979) (Genome Aggregation Database March 6, 2019, v2.1.1). The p.M52 residue is conserved in mammals and computational analyses (MUT Assesor, PolyPhen-2, SIFT, MutationTaster, Revel, FATHMM, MetaLR, DANN) suggest that the variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (Splice AI exome) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. -
Observed in the germline of individuals with acute myeloid leukemia and acute lymphocytic leukemia in published literature (PMID: 29365323, 28801348, 34166225); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 23753029, 29365323, 28801348, 34166225, 37647632) -
Hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1 Benign:1Other:1
- -
Variant interpreted as Likely benign and reported on 06-10-2020 by Lab or GTR ID 500031. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. -
not specified Uncertain:1
- -
Inborn genetic diseases Uncertain:1
The p.M52K variant (also known as c.155T>A), located in coding exon 3 of the RUNX1 gene, results from a T to A substitution at nucleotide position 155. The methionine at codon 52 is replaced by lysine, an amino acid with similar properties. This variant was reported in multiple individuals with features consistent with RUNX1 familial platelet disorder with associated myeloid malignancies (Mendler JH et al. Haematologica, 2013 Aug;98:e92-4; Drazer MW et al. Blood Adv, 2018 Jan;2:146-150; Li Y et al. J Clin Invest, 2021 Jun;131:). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. -
RUNX1-related disorder Uncertain:1
The RUNX1 c.155T>A variant is predicted to result in the amino acid substitution p.Met52Lys. This variant was reported as a germline variant in individuals with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (Mendler et al. 2013. PubMed ID: 23753029; Drazer et al. 2018. PubMed ID: 29365323; Li et al. 2021. PubMed ID: 34166225). One patient with AML also harbored variants in NPM1 and DNMT3A; therefore, it is unclear whether the RUNX1 variant was the primary cause of disease (Mendler et al. 2013. PubMed ID: 23753029). This variant is reported in 0.050% of alleles in individuals of European (non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/21-36259336-A-T). It is interpreted as a variant of uncertain significance by the ClinGen Myeloid Malignancy Variant Curation Expert Panel (https://www.ncbi.nlm.nih.gov/clinvar/variation/239044/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Hereditary cancer-predisposing syndrome Uncertain:1
- -
Anaplastic ependymoma Uncertain:1
- -
Hereditary thrombocytopenia and hematologic cancer predisposition syndrome Benign:1
The NM_001754.4:c.155T>A (p.Met52Lys) is a missense variant. This variant has a MAF of 0.0007121 (0.071%, 840/1179678, 840 alleles) in the European (non-Finnish) subpopulation of the gnomAD v4.1.0 cohort is between 0.00015 (0.015%) and 0.0015 (0.15%) (BS1). In summary, this variant meets criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BS1. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at